Key Factors for Ovarian Cancer Market Growth 2020

1
Frontier Pharma Ovarian Cancer - Identifying and
Commercializing First-in-Class Innovation
Published on - 01 December, 2015 Number of
pages 65 Single User Price 6995
Ovarian cancer is the sixth most common cancer
in females and it also has the highest mortality
rate of gynecological cancers. The five-year
survival rate is approximately 45, although the
disease is ultimately fatal in the majority of
patients due to a high rate of recurrence.
2
Ovarian cancer is the sixth most common cancer in
females and it also has the highest mortality
rate of gynecological cancers. The five-year
survival rate is approximately 45, although the
disease is ultimately fatal in the majority of
patients due to a high rate of recurrence.
Surgery is generally considered an effective
treatment for localized tumors, however the
management of recurrent and later-stage disease
is largely reliant on cytotoxic chemotherapy
regimens. A highly active ovarian cancer
pipeline contains an array of diverse molecule
types and molecular targets, in contrast to the
market. With the diversity in the pipeline, there
is hope that innovative products can make it to
market to provide patients with greater
therapeutic options, while meeting unmet needs
within ovarian cancer. There are 179 ovarian
cancer pipeline products associated with a
first-in-class molecular target representing 52
of the total pancreatic cancer pipeline products
that have a disclosed molecular target. Such a
diverse and innovative pipeline implies that
approaches to ovarian cancer treatment are
changing and first-in-class development is
playing a significant role in this.
Click Here To Check Complete Report
3
Scope of the Report Chemotherapy based regimens
continue to dominate the market, which has seen
few new entrants over the past decade. Lynparza
(olaparib) is a key new entrant however it is
only effective in a small patient subset. The
pipeline places increased focus on targeted
therapies, including a large number of therapies
targeting common oncogenic pathways and signaling
intermediates such as PI3K/Akt. Will pipeline
diversity translate to clinically and
commercially successful therapies? How are
common target families, such as intracellular
signal transduction associated with
pathophysiology? 52 of pipeline products act on
a first-in-class target, which is higher than the
oncology and industry averages. Why is the
greatest number of first-in-class products seen
in signal transduction? First-in-class products
differ substantially in their clinical potential,
based on their alignment to disease causing
pathways
Download Sample Brochure
4
Reasons to buyThis report will allow you to
-  Understand the current clinical and commercial
landscape. This includes a comprehensive study of
disease pathogenesis, diagnosis, prognosis and
the available treatment options available at each
stage of diagnosis. Visualize the composition of
the ovarian cancer market in terms of dominant
molecule types and targets, highlighting what the
current unmet needs are and how they can be
addressed. This knowledge allows a competitive
understanding of gaps in the current
market. Analyze the ovarian cancer pipeline, and
stratify by stage of development, molecule type
and molecular target. There are promising signs
in the pipeline that the industry is seeking
novel approaches the treating ovarian
cancer. Assess the therapeutic potential of
first-in-class targets. Using a proprietary
matrix, first-in-class products have been
assessed and ranked according to clinical
potential. Promising early-stage targets have
been further reviewed in greater
detail. Identify commercial opportunities in the
ovarian cancer deals landscape by analyzing
trends in licensing and co-development deals and
producing a curated list of ovarian cancer
therapies that are not yet involved in deals and
may be potential investment opportunities.
Make an Inquiry Before Buying
5
Frontier Pharma Ovarian Cancer - Identifying and
Commercializing First-in-Class Innovation
A detailed qualitative analysis of the factors
responsible for driving and restraining growth of
Frontier Pharma Frontier Pharma Ovarian Cancer
- Identifying and Commercializing First-in-Class
Innovation are provided in the report.
Contact 1-302-684-6088 sales_at_marketintelreports.c
om www.marketintelreports.com
Click here to order a copy of Ovarian Cancer
Market Report